安捷伦科技宣布,其PD-L1 IHC 22C3 PharmDx检测试剂已获得欧盟监管机构批准,适用于上皮性卵巢癌、输卵管癌或原发性腹膜癌患者的伴随诊断。这一批准标志着该重要检测产品在欧盟市场的应用范围得到进一步扩展。
此次获批意味着,临床医生现在可以依据该检测结果,更精准地识别可能从特定免疫疗法中获益的上述癌症患者。检测通过评估肿瘤细胞中PD-L1蛋白的表达水平,为个体化治疗决策提供关键依据。这一进展有望为欧洲地区的相关癌症患者带来新的治疗选择与希望。
安捷伦科技宣布,其PD-L1 IHC 22C3 PharmDx检测试剂已获得欧盟监管机构批准,适用于上皮性卵巢癌、输卵管癌或原发性腹膜癌患者的伴随诊断。这一批准标志着该重要检测产品在欧盟市场的应用范围得到进一步扩展。
此次获批意味着,临床医生现在可以依据该检测结果,更精准地识别可能从特定免疫疗法中获益的上述癌症患者。检测通过评估肿瘤细胞中PD-L1蛋白的表达水平,为个体化治疗决策提供关键依据。这一进展有望为欧洲地区的相关癌症患者带来新的治疗选择与希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.